Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00263666
First received: December 8, 2005
Last updated: October 27, 2011
Last verified: October 2011

December 8, 2005
October 27, 2011
March 2005
February 2008   (final data collection date for primary outcome measure)
Number of Subjects Reporting Grade "2" or Grade "3" Fever, Vomiting or Diarrhea. [ Time Frame: Within the 15-day solicited follow-up period after any dose. ] [ Designated as safety issue: No ]

Symptoms reported in the table include:

Fever: temperature (axillary route) > 38.0 degree Celsius (°C); Diarrhea: ≥ 4 looser than normal stools/day; Vomiting: ≥ 2 episodes of vomiting/day.

% of subjects who report grade "2" or grade "3" fever, vomiting or diarrhea during the 15-day f/u period after each dose.
Complete list of historical versions of study NCT00263666 on ClinicalTrials.gov Archive Site
  • Number of Subjects Reporting Any Unsolicited Symptoms. [ Time Frame: Within 30 days after each dose ] [ Designated as safety issue: No ]
    An unsolicited symptom was any spontaneously reported untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
  • Number of Subjects Reporting Any Serious Adverse Events. [ Time Frame: Until 2 months after dose 3 (for subjects RV negative at Day 42 post-dose 3) or until end of RV shedding (for subjects who shed RV at Day 42 post-dose 3). ] [ Designated as safety issue: No ]

    A serious adverse event (SAE) is any untoward medical occurrence that:

    results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.

  • Number of Subjects Reporting Each Type of Solicited Symptom. [ Time Frame: Within the 15-day solicited follow-up period after each dose ] [ Designated as safety issue: No ]
    Solicited symptoms included Cough, Diarrhea (3 or more looser than normal stools/day), Fever (axillary temperature ≥ 37.5°C), Irritability, Loss of appetite, and Vomiting.
  • The Number of Subjects With no Evidence of Immunosuppression and Moderate/ Severe Suppression, Based on CD4+ Absolute Cell Count and CD4+ Percent. [ Time Frame: At the screening visit and 2 months after dose 3 (Visit 4). ] [ Designated as safety issue: No ]
    Severe suppression: CD4+ cells/microliter (μl) < 750 and CD4+ percent < 15 percent (%); No evidence of suppression: CD4+ cells/μl ≥ 1500 and CD4+ percent ≥ 25%; Moderate suppression = all other CD4+ cell count and CD4+ % combinations.
  • Human Immunodeficiency Virus (HIV) Viral Load [ Time Frame: At the screening visit and 2 months after dose 3. ] [ Designated as safety issue: No ]
    Mean and standard deviation of the base-10 logarithm of HIV-1 ribonucleic acid (RNA) copies per milliliter (mL).
  • Number of Subjects Who Seroconverted Against Rotavirus [ Time Frame: Two months after dose 3 ] [ Designated as safety issue: No ]
    A subject with anti-rotavirus Immunoglobulin (IgA) antibody concentration < 20 units/milliliter (U/mL) before vaccination and ≥ 20 U/mL after vaccination is considered as seroconverted.
  • Number of Subjects With Vaccine Take. [ Time Frame: Two months after the dose 3 ] [ Designated as safety issue: No ]
    Vaccine take: appearance of serum IgA to rotavirus at a concentration of ≥20 U/ml or rotavirus shedding in any stool sample collected from the Screening Visit to 2 months after dose 3 for subjects initially negative for rotavirus.
  • Serum Rotavirus Immunoglobulin A (IgA) Antibody Concentrations. [ Time Frame: Two months after dose 3 ] [ Designated as safety issue: No ]
    Concentrations are given as geometric mean concentrations (GMC) for anti-rotavirus IgA antibodies.
  • Number of Subjects With Anti-polyribosyl Ribitol Phosphate (PRP) Antibody Concentrations More Than or Equal to the Cut-off Value. [ Time Frame: Two months after dose 3 ] [ Designated as safety issue: No ]
    Cut-off values for anti-PRP antibody concentrations were ≥ 0.15 and ≥ 1.0 microgram/milliliter (µg/mL).
  • Geometric Mean Concentration for Anti-PRP Antibodies. [ Time Frame: Two months after dose 3 ] [ Designated as safety issue: No ]
  • Number of Subjects With Anti-diphtheria and Anti-tetanus Toxoids Antibody Concentrations More Than or Equal to the Cut-off Value [ Time Frame: Two months after dose 3 ] [ Designated as safety issue: No ]
    The cut-off value was ≥ 0.1 International Units/milliliter (IU/mL)
  • Geometric Mean Concentration for Anti-diphtheria and Anti-tetanus Toxoids Antibodies. [ Time Frame: Two months after dose 3 ] [ Designated as safety issue: No ]
  • Number of Subjects With Anti-hepatitis B (HBs) Antibody Concentrations More Than or Equal to the Cut-off Value [ Time Frame: Two months after dose 3 ] [ Designated as safety issue: No ]
    The cut-off value was ≥ 10 milli international units/milliliter (mIU/mL).
  • Geometric Mean Concentration for Anti-HBs Antibodies. [ Time Frame: Two months after dose 3 ] [ Designated as safety issue: No ]
  • Number of Subjects With Anti-Bordetella Pertussis (BPT) Antibody Concentrations More Than or Equal to the Cut-off Value [ Time Frame: Two months after dose 3 ] [ Designated as safety issue: No ]
    The cut-off value was ≥ 15 Enzyme Linked Immunosorbent Assay Unit/milliliter(EL.U/mL).
  • Geometric Mean Concentration for Anti-BPT Antibodies. [ Time Frame: Two months after dose 3 ] [ Designated as safety issue: No ]
  • Number of Subjects With Anti-polio Types 1, 2 and 3 Antibody Titers More Than or Equal to the Cut-off Value [ Time Frame: Two months after dose 3 ] [ Designated as safety issue: No ]
    The cut-off value was ≥ 1:8. The lowest dilution at which serum samples were tested was 1:8, from which a test was considered positive.
  • Geometric Mean Titer for Anti-polio Types 1, 2 and 3 Antibodies. [ Time Frame: Two months after dose 3 ] [ Designated as safety issue: No ]
  • Rotavirus Antigen Excretion in Stool Samples [ Time Frame: At day of each vaccination and at planned days following each vaccine dose until 2 months after dose 3 or until end of RV shedding ] [ Designated as safety issue: No ]
    Number of subjects with rotavirus detected by Enzyme Linked Immunosorbent Assay (ELISA) in stool samples collected from Dose 1 until study end
  • Rotavirus in Diarrheal Stool Samples [ Time Frame: From Dose 1 until 2 months after dose 3 or until end of RV shedding ] [ Designated as safety issue: No ]
    Number of subjects reporting at least one rotavirus (vaccine strain or wild type rotavirus) gastroenteritis episode.
  • Rotavirus Vaccine Strain Identification if Applicable. [ Time Frame: From dose 1 until 2 months after dose 3 or until end of RV shedding ] [ Designated as safety issue: No ]
  • Enteric Pathogens Identification. [ Time Frame: From Dose 1 until 2 months after dose 3 or until end of RV shedding ] [ Designated as safety issue: No ]
    Number of gastroenteritis (GE) episodes classified by enteric pathogen tests results.
Occurrence of solicited symptoms within the 15-day f/u period, unsolicited symptoms within the 31-day f/u and SAEs throughout the study. CD4 count and HIV viral load at screening and Visit 4. Anti-rotavirus IgA antibody concentration and seroc
Not Provided
Not Provided
 
A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa
Assess the Safety, Reactogenicity and Immunogenicity of 3 Doses of GSK Biologicals' HRV Vaccine Administered to HIV Infected Infants at 6, 10 and 14 Weeks of Age in South Africa

The aim of this study is to evaluate the reactogenicity, safety and immunogenicity of GSK Biologicals' human rotavirus (HRV) vaccine given concomitantly with routine vaccines including OPV in HIV positive infants. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

HIV infected infants as determined prior to study entry (screening) and asymptomatic or mildly symptomatic (WHO stages I and II) of disease will be enrolled. The study will have two groups: Group HRV and Group Placebo. Three-dose immunisation will be administered at approximately 6, 10, and 14 weeks of age. Routine EPI (Expanded Program on Immunisation) vaccinations will be administered concomitantly with the study vaccines. At the time of first dose, subjects will be aged 6 to 10 weeks. This study will evaluate safety, reactogenicity and immunogenicity of the HRV vaccine relative to the placebo.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Rotavirus Gastroenteritis
  • Biological: Rotarix
    Oral vaccination
  • Biological: Placebo
    Oral administration
  • Biological: TritanrixTM-HB+Hib
    Concomitant routine vaccination, IM administration
  • Biological: SabinPolioTM vaccine
    Oral administration, concomitant routine vaccination
  • Experimental: Rotarix Group
    Subjects received 3 dose of Rotarix vaccine co-administered with routine Tritanrix TM, HepB Hib and Polio Sabin TM vaccines.
    Interventions:
    • Biological: Rotarix
    • Biological: TritanrixTM-HB+Hib
    • Biological: SabinPolioTM vaccine
  • Placebo Comparator: Placebo Group
    Subjects received 3 dose of placebo co-administered with routine Tritanrix TM, HepB Hib and Polio Sabin TM vaccines.
    Interventions:
    • Biological: Placebo
    • Biological: TritanrixTM-HB+Hib
    • Biological: SabinPolioTM vaccine

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
100
February 2008
February 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
  • A male or female between, and including 6 and 10 weeks of age at the time of the first vaccination.
  • Written informed consent obtained from the parents or guardians of the subject
  • Documented HIV status of the subject as confirmed by PCR.
  • HIV asymptomatic and HIV mildly symptomatic; Stages I and II disease according to WHO's most recent classification for HIV stages in infants and children.
  • Born after a gestation period of 36 to 42 weeks.

Exclusion Criteria:

  • Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Previous routine vaccination except OPV, BCG and HBV vaccination at birth
  • Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the GI tract or other serious medical condition as determined by the investigator.
  • History of allergic disease or reaction likely to be exacerbated by any component of the vaccine.
  • Acute disease at time of enrolment.
  • Gastroenteritis within 7 days preceding the study vaccine administration.
  • Previous confirmed occurrence of RV gastroenteritis.
  • Other conditions which in the opinion of the investigator may potentially interfere with interpretation of study outcomes.
  • HIV moderately and severely symptomatic: stages III and IV according to WHO's recent classification.
  • Administration of immunoglobulins and/or blood products since birth or planned administration during the study period.
Both
6 Weeks to 10 Weeks
No
Contact information is only displayed when the study is recruiting subjects
South Africa
 
NCT00263666
444563/022
Not Provided
Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
October 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP